Abstract: Neurotrophic factors have been widely suggested as a treatment for multiple diseases including motorneuron pathologies, like Amyotrophic Lateral Sclerosis. However, clinical trials in which growth factors have been systematically administered to Amyotrophic Lateral Sclerosis patients have not been effective, owing in part to the short half-life of these factors and their low concentrations at target sites. A possible strategy is the use of the atoxic C fragment of the tetanus toxin as a neurotrophic factor carrier to the motorneurons.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown aetiology characterized by degeneration of motorneurons in the spinal cord, brain stem, and motor cortex. At present, treatment for ALS is mainly palliative [1] , although the administration of neurotrophic growth factors as a means to protect motorneurons is being analysed [2] . In vitro studies demonstrated that several neurotrophic factors delay motorneuron degeneration [3] [4] [5] [6] . However, clinical trials using subcutaneous and intrathecal neurotrophic factors caused several side effects such as weight loss, fever, cough, fatigue and behavioural changes [7] [8] [9] [10] [11] [12] .
The failure of these trials might be attributed in part to insufficient trophic factor delivery to motorneurons and to a non-specific delivery to non-motor systems [13] . Several authors have focused their research on the use of viral vectors transfer systems to deliver in vivo neurotrophic factors to neurons. These attempts successfully increase the survival of motorneurons and prolong the life span [4, 14] . However, these vectors also show poor efficiency in binding motorneuron terminals [15, 16] and poor specificity due to their tropism to a variety of host cells. In addition to numerous efforts to avoid virus disadvantages, some researchers involved in the adenovirus gene therapy are also proposing the use of peptides with enhanced neurotropism as an
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Neurotrophic factor and the C fragment of the tetanus toxin genetic fusion protein alternative [13] . Moreover, safety concerns regarding the use of virus in humans make non viral delivery systems an attractive alternative. Neuronal toxins could be used for this purpose.
We and other researchers have previously proposed the atoxic C-terminal fragment of the tetanus toxin (TTC) as a good alternative to reach motorneurons after intramuscular injection [17] . The fragment TTC is necessary (and sufficient) for neuron binding and internalisation, retrograde and transynaptic transport [18, 19] . Moreover, studies both in vitro and in vivo demonstrated that TTC has the capacity to deliver other large proteins linked by chemical or genetic fusion such as horseradish perodixase [20] , b-galactosidase [17, 21] , superoxide dismutase [22] [23] [24] , cardiotrophin-1 [25] and survival motor neuron factor in neurons [26] . The above experiments support the idea that TTC is a promising system for delivering biological activity to the Central Nervous System. In the last year, Larsen et al. demonstrated that the chemical fusion between GDNF and TTC retained the GDNF activity in vivo, and they proposed TTC like a non-viral vehicle to motorneurons [27] . A putative strategy is gene therapy but genetic fusions are necessary for this purpose. However, it has been proposed that genetic fusion of trophic factors to larger proteins could alter their folding and conformation, thereby undermining their neuroprotective properties [13] . The aim of the present work is the production of a recombinant genetic fusion protein between BDNF and TTC and the study of BDNF functional maintenance.
Experimental Procedures

Plasmid construction: Fusion protein and BDNF expression vectors
pGex BDNF-TTC and pGex BDNF plasmids were generated from pcDna3.1-BDNF (pre-protein form). Coding regions of the BDNF mature form, including restriction sites in 5' and 3' ends, were isolated using PCR and site-directed mutagenesis. PCR primers used were: forward BDNF 1 (5´-C C G C G T G G AT C C C A C T C T G A C C C T G C C -3´) and reverse BDNF 2 (5´-CCCGGGGAATCATCTTCCCCTTTTAAT-3´) to mature BDNF and forward BDNF 1 reverse BDNF 3 (5´-CTGGGGATCCTCTTCCCCTTTTAAT-3´) to fusion vector. Products were cloned in frame with TTC into pGex TTC and pGex 4T-2 (Amersham).
Recombinant protein purification
Recombinant proteins were purified from Escherichia coli strain Bl21-C43 as described by Coen et al. [17] . Eluted protein concentrations were achieved by centrifugation in Amicon; 50,000 and 10,000 molecular weight cutoff membrane pre-treated with 5% Tween 20. Protein expression and purity were evaluated by Coomassie blue staining and Western Blot analysis (SDS-PAGE 10% and PVDF, 0.45 mm porosity, Amersham). Immunoblotting membranes were incubated with the rabbit polyclonal antibodies, anti human BDNF (1/500, Santa Cruz Biotechnology) and anti TTC (1/500, Eurogentec) and revealed with a Vectastain ABC-alkaline phosphatase kit (Vector Laboratories) and DAB development.
Immunodetection of Akt in cortical neuronal cells
Cortical tissues were dissected from newborn (P0-P2) Swiss mice, which were manipulated and sacrificed following the recommendations of the European Community guidelines for laboratory animal handling. Dissociated cortical neurons obtained by 0.25% trypsin, followed by 0.1 mg/ml DNase treatments and washed with DMEM/F12 (Invitrogen, Life Technologies) supplemented with 10% FBS, were plated on poly-L-Lysine coated coverslips at a density of 20,000 cells/cm 2 . Cells were cultured with DMEM/F12 supplemented with 5 units/ml penicillin/streptomycin and 100 mg/ml transferrin, 20 nmol/l selenium, 20 nmol/l hydrocortisone, 20 nmol/l progesterone, and 5 mg/mL insulin (Sigma-Aldrich) at 37°C/5% CO 2 /100% humidity for 2 days. This medium was replaced with Neurobasal medium supplemented with B27 (Invitrogen, Life Technologies) for 14 days, renewed every 3 to 4 days.
Cultured primary cortical neurons were incubated with 10ng/mL BDNF, BDNF-TTC, TTC or without protein for 1 hour at 37°C. After several steps of washing with PBS (phosphate-buffered saline containing 0.1 mmol/l CaCl 2 and 0.1 mmol/l MgCl 2 ) and fixing with parafolmadehyde 4% in PBS, samples were incubated for 1 h in an antibody buffer (6% BSA and 0.3% Triton X-100 in PBS). Incubation with the primary polyclonal rabbit anti p-Akt antibody (1:1000; Santa Cruz Biothechnology. Inc., CA, USA) was performed in the antibody buffer for 1 h 30 min at RT. After washing, incubation with the secondary antibody conjugated to Alexa Fluo® 546 (1:1000; goat anti rabbit IgG Molecular Probes, Inc.) proceeded for 1h at RT. Coverslips mounted in Fluoromount-G solution were visualized by confocal analysis. Images were acquired on an Axiovert 200M laser scanning confocal microscope (Zeiss LSM-510; version 3.2) through a 63x/1.4 NA, oil-immersion objective. The pinhole aperture was set to 1 airy unit, and images were digitised at 8-bit resolution into a 512 x 512 array. To be able to compare the intensity of the Akt staining between different experimental conditions, laser illumination, photomultiplier gain with respect to linear response, and other acquisition variables were standardized. Using the Zeiss LSM-510 software the fluorescence global intensity [sum of intensity value (0 to 255) associated with each pixel intensity] was then measured in predefined area per square micrometer, which thus defined the fluorescence level expressed as arbitrary units. This cumulated fluorescent intensity was an accurate representation of the quantity of Akt protein in each cell.
Apoptosis quantification in Neuro2-A cells
Mouse neuroblastoma Neuro2-A cells were grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 10 U/mL penicillin and 10 mg/ml streptomycin. Cells were plated on poly-L-lysine coated coverslips and cultured at 37ºC/5% CO 2 /100% humidity. The medium was renewed every 3 days.
Apoptosis in Neuro 2A cells (2.5x10 5 ) was induced by serum deprivation for 48 and 72 hours. The fusion protein BDNF-TTC was added at doses of 10, 50 and 250 ng/mL culture. Equivalent doses of BDNF and TTC were established as controls. After trypsinization and PBS washing, centrifuged cells were resuspended in a binding buffer (0.14 M NaCl; 5 M CaCl 2 ; 0.01 M Hepes pH 7.4), incubated with annexin V-APC for 15 min, stained with propidium iodide and diluted in the binding buffer. Cells were analysed using a FACSCalibur flow cytometer (acquisition at 660 nm for annexin V-APC and 562-588 nm for PI). Excitation was at 650 nm and the emitted green fluorescence of Annexin V (FL4) and red fluorescence of PI (FL3) were collected using a 525 and 575 nm band pass filter, respectively. A total of at least 30,000 cells were analysed per sample. Light scatter was measured on a linear scale of 1024 channels and fluorescence intensity on a logarithmic scale. The amount of early apoptosis cells was determined as the percentage of Ann V+/PI−.
Data analysis
In the immunodetection of Akt in cortical neuronal cells, 25 neurons selected randomly and objectively for each condition were analysed. Percentages of apoptotic cells were obtained from three independent Fluorescence Activated Cell Sorting experiments. Results were expressed as the mean ± SD. The statistical studies were based on univariant ANOVA tests and intergroup differences were analysed using Scheffe tests.
Results
Purification of recombinant proteins
Direct mutagenesis has been used to clone the coding regions of BDNF, TTC and BDNF-TTC fusion protein into expression vectors. The identity of purified proteins was confirmed by Western Blotting using two specific antibodies. Anti-BDNF revealed the expected bands of 14 kDa for BDNF and 70 kDa for BDNF-TTC. On the other hand, the antibody against TTC displayed a band of 50 kDa for TTC and the same 70 kDa for BDNF-TTC (Figure 1) . The quantity obtained for recombinant proteins was established by SDS-PAGE and Coomassie blue staining using a BSA protein standard. Production varied between proteins: 100 mg per litre of culture for TTC, 20 mg/l for BDNF and 6.1 mg/l for BDNF-TTC. 
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BDNF-TTC fusion protein induces Akt phosphorylation in cultured cortical neurons
Immunodetection of Akt after incubation for 1 hour with the different proteins was used to check the survival activation signal. Evident differences in the signals were observed after incubation with the three proteins and the control (Figure 2A , B, C and D). The stronger signal was observed with BDNF, followed by the fusion protein and finally TTC alone. These differences were quantified by inmunofluorescence measurement for confocal microscopy as described in the Experimental Procedures section. Samples incubated with BDNF (121.00 + 40.46) and BDNF-TTC (104.88 + 55) showed a significant activation of Akt along the cell in contrast with the negative controls, with a value of 76.04 + 22.35. Moreover, samples incubated with TTC showed activation, with a value of 83.10 + 38.98, but no significant differences were observed with the control.
BDNF-TTC has a more noticeable effect than TTC alone in in vitro early apoptosis inhibition
The functionality of BDNF and BDNF-TTC proteins was assessed by analysing the effect of these proteins on the inhibition of apoptosis induced in Neuro2A cells using serum deprivation. Quantification of apoptosis was performed using an Annexin V staining protocol to determine the exposure of phosphatidylserine in the cell surface. Forty eight hour treatment with BDNF showed differences with the control for all the doses studied. The other proteins did not show any effect at this time although BDNF-TTC displayed a tendency for apoptosis inhibition but this difference was not statistically significant. This tendency was confirmed at 72 hours. The three recombinant proteins (BDNF, BDNF-TTC and TTC) were able to inhibit apoptosis after serum deprivation in Neuro2A ( Figure 3A) after 72 hours. BDNF-TTC treatment at low dose (10 ng/ml) decreased the percentage of apoptotic cells six times (6.55% + 0.29) compared to the control (40.1% + 0.01) and ten times (3.97 + 0.18) at the highest dose (250 ng/ml). The neurotrophic factor BDNF also showed an important significant antiapoptotic effect (5.78% + 1.1 at 10 ng/ ml and 5.52% + 0.01 at 250 ng/ml). BDNF-TTC had a similar effect in the inhibition of apoptosis than the neurotrophic factor alone.
Discussion
We report here the production and subsequent functionality test of a fused protein containing the Brain Derived Neurotrophic Factor linked to the atoxic C fragment of the tetanus toxin. The production of TTC by E. coli was as expected [17] . As described by other authors, the bacterial cells did not yield a high quantity of mature BDNF [28] . A possible cause for the levels of protein obtained could be the eukaryotic origin of BDNF. This could induce the formation of inclusion bodies in E. coli, which has been previously described for other eukaryotic proteins [29] . Eighty per cent of BDNF protein production can be contained in the insoluble fraction of the cell lysate; however, this protein has low biological activity and seems to have a different secondary structure [28] . On the other hand, the use of animal cells to produce high quantities of biologically active BDNF has been also reported [30] . However, these methods require special needs for culture and proliferation control reducing the productivity of protein purification. Therefore, we can consider that our selected synthesis method with E. coli is the most adequate for protein production, in terms of economy and efficiency, sacrificing the loss of proteins in inclusion bodies.
Finally, differences observed for BDNF and BDNF-TTC production could be due to their different molecular weight. The smaller size of BDNF might attribute a reduction in the protein surface, reducing possible interactions with endogenous bacterial mechanisms and yielding to a lower formation of inclusion bodies. In any case, the quantity obtained for the different recombinant proteins was sufficient to analyse their biological activity through the following experiments.
In order to check the BDNF-TTC functionality, we first analysed the activation of Akt. Akt is a general mediator of survival signals and is both necessary and sufficient for the survival of eukaryotic cells [31] . This pathway is especially implicated in neuronal survival and it is shared by the signalling cascades activated neurotrophic factors [32, 33] . In addition, BDNF and TTC are able to activate survival pathways such as Akt, PLCg-1 or MAPK in cultured cortical and cerebellar granule neurons. The Akt pathway is activated by the C fragment of the tetanus toxin after 30 minutes of incubation with neuronal cultures, and afterwards the activation decreases [34, 35] . On the contrary, the activation with BDNF extends after this time, up to 240 minutes [36] . For this reason, in order to know if the neurotrophic factor remained active, the induction of the Akt pathway was analysed after 60 minutes in cortical neuronal cells treated with the BDNF-TTC, in which time no TTC effect should be observed. Our results demonstrated that BDNF can activate the Akt pathway even when the neurotrophic factor was fused at TTC, and their functionality is partially maintained. We can conclude that Akt activation was a cause of the BDNF presence in the fusion protein, and the activated Akt is translocated into the nucleus as other neurotrophic factors are [37, 38] . We suppose that the mechanism inhibiting apoptosis is through the Akt activation, which translocates to the nucleus. In the nucleus it can phosporylate AFX (Forkhead family transcription proteins), related with apoptosis activation, what inhibits it by translocation to the cytoplasm [39] . In addition to the analysis of these pathways, we were also interested in the direct antiapoptotic effect of fusion protein. For this purpose, we have analysed the effects of the three proteins on apoptosis inhibition in vitro. Moreover, this assay could clarify if the effect of fusion protein was higher or lower than the one of TTC alone. Our experiments indicate that the fused protein BDNF-TTC is functional in early apoptosis inhibition processes of the Neuro2A cell line as described for BDNF [40, 41] . The present study, as well as previous work has shown that TTC can activate survival pathways in cells [34, 35, 42, 43] . We report here that TTC also displays an antiapoptotic effect compared to control, although this effect was lower than the ones resulting from the treatment with the other two recombinant proteins ( Figure 3B ) and also given that the TTC effect was lower than the others, we consider that the activity of the neurotrophic factor was maintained in our study.
Why was BDNF-TTC activity similar to BDNF at 72 hours? This fact could be explained by two different hypotheses. Firstly, TTC could retard the effect of BDNF, therefore needing more time to have the some effect as the BDNF alone. Secondly, BDNF activity could be Antiapoptotic activity maintenance of Brain Derived Neurotrophic factor and the C fragment of the tetanus toxin genetic fusion protein partially affected in the fusion protein; however, the antiapoptotic effect of TTC could make up for this affect by increasing the activity of BDNF-TTC to identical levels than BDNF alone.
BDNF can rescue different kinds of neurons, as striatal, cerebellar neurons or motorneurons from apoptosis [44] [45] [46] . In this way, BDNF administration has been proposed for possible therapies in neurodegenerative diseases like Amyotrophic Lateral Sclerosis, Parkinsons or Alzheimers. However, these factors presented poor access to motorneurons [47] and several side effects were observed. The TTC could solve this problem and this protein could have a possible therapeutic use in neuromuscular diseases like ALS [21, 35] . The combination of these proteins in the treatment of different neurodegenerative diseases could be a powerful tool for gene therapy.
We propose the use of BDNF-TTC recombinant protein as a new tool for antiapoptotic signal delivery to the Central Nervous System after intramuscular injections, and as a possible gene therapy for neurodegenerative diseases affecting motorneurons.
